BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18037776)

  • 1. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
    Shimosawa T; Gohchi K; Yatomi Y; Fujita T
    Hypertens Res; 2007 Sep; 30(9):831-7. PubMed ID: 18037776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study.
    Toh R; Ishida T; Nishimura K; Nonaka H; Inoue Y; Kitagawa Y; Suematsu M; Miki T; Emoto N; Hirata K
    Hypertens Res; 2012 Nov; 35(11):1080-6. PubMed ID: 22786569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial.
    Nishiwaki M; Hosoai H; Ikewaki K; Ayaori M; Yamashita T; Shige H; Higashi K; Nashida Y; Shimizu S; Kijima F; Yokoyama M; Nakamura H;
    Clin Ther; 2013 Apr; 35(4):461-73. PubMed ID: 23490288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
    Volpe M; Miele C; Haag U
    Clin Drug Investig; 2009; 29(6):381-91. PubMed ID: 19432498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
    Mengden T; Uen S; Bramlage P
    Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
    Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
    Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
    Edes I;
    Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
    Ohma KP; Milon H; Valnes K
    Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
    Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y;
    Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
    Zappe D; Papst CC; Ferber P;
    Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.
    Fujiwara W; Izawa H; Ukai G; Yokoi H; Mukaide D; Kinoshita K; Morimoto S; Ishii J; Ozaki Y; Nomura M
    Heart Vessels; 2013 May; 28(3):316-22. PubMed ID: 22447467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients.
    Uchiwa H; Kai H; Iwamoto Y; Anegawa T; Kajimoto H; Fukuda K; Imaizumi T; Fukumoto Y;
    Clin Exp Hypertens; 2018; 40(3):267-273. PubMed ID: 29083936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.